Cost Effectiveness of Secukinumab for the Treatment of Active Ankylosing Spondylitis in the UK

OBJECTIVE: To determine the cost effectiveness of secukinumab, a fully human interleukin-17A inhibitor, for adults in the UK with active ankylosing spondylitis (AS) who have not responded adequately to previous treatment with conventional care (CC; biologic-naïve population) or previous biologic the...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Pharmacoeconomics
Autors principals: Emery, Paul, Van Keep, Marjolijn, Beard, Steve, Graham, Chris, Miles, LaStella, Jugl, Steffen Marc, Gunda, Praveen, Halliday, Anna, Marzo-Ortega, Helena
Format: Artigo
Idioma:Inglês
Publicat: Springer International Publishing 2018
Matèries:
Original Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6021464/
https://ncbi.nlm.nih.gov/pubmed/29797186
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40273-018-0675-9
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars